Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DT-101
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Access Biotechnology
Deal Size : $140.0 million
Deal Type : Series A Financing
Draig Launches with $140M to Advance Therapies for Neuropsychiatric Disorders
Details : The financing aims to advance the clinical development of DT-101, which are being evaluated for the treatment of Major Depressive Disorder.
Product Name : DT-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 18, 2025
Lead Product(s) : DT-101
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Access Biotechnology
Deal Size : $140.0 million
Deal Type : Series A Financing
Reset All
